Patient Site Healthcare Professional Site
VIVITROL (naltrexone for extended-release injectable suspension) VIVITROL: A Treatment Option For The Daily Struggle Against Alcohol Dependence. One dose all month long.
Patient Site
Patient Information
Send to a Friend
Homepage About Vivitrol Links Contact Us SEARCH
Contact Us Graphic: Contact Us
My Path to Recovery
CONTACT US

If you would like to receive additional information on VIVITROL and other
Cephalon products in the future, please complete the form below.



  *First Name:
  *Last Name:
  *Mailing Address:
    Address 2:
  *City:
  *State:
  *Zip:
    Phone Number:
  *Email Address:
 
The information that will be supplied to you is intended for US residents only. If you are requesting information be mailed to you, you must supply a US address.

*Privacy Statement:
Cephalon respects your right to have personal and medical information kept confidential. Cephalon and companies working with Cephalon will use the information you provide in accordance with our privacy policy.
 
By clicking here and submitting this form you agree that Cephalon and companies working with Cephalon may:
  • Use your information to help develop new Cephalon products, services, and programs you may find useful
  • In the future, provide you with materials you may find useful
  • Contact you about health-related topics
By clicking here you indicate that you want us to use the information you are now providing only to send you the VIVITROL information you requested.
CANCEL   SUBMIT
  * Denotes Required Fields





Locate a Physician
Important Safety Information
Naltrexone has the capacity to cause hepatocellular injury when given in excessive doses. Naltrexone is contraindicated in acute hepatitis or liver failure, and its use in patients with active liver disease must be carefully considered in light of its hepatotoxic effects. The margin of separation between the apparently safe dose of naltrexone and the dose causing hepatic injury appears to be only five-fold or less. VIVITROL does not appear to be a hepatotoxin at the recommended doses. Patients should be warned of the risk of hepatic injury and advised to seek medical attention if they experience symptoms of acute hepatitis. Use of VIVITROL should be discontinued in the event of symptoms and/or signs of acute hepatitis.
VIVITROL is indicated for the treatment of alcohol dependence in patients who are able to abstain from alcohol in an outpatient setting prior to initiation of treatment with VIVITROL.

Patients should not be actively drinking at the time of initial VIVITROL administration.

Treatment with VIVITROL should be part of a comprehensive management program that includes psychosocial support.